Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brain tumor endpoints

Executive Summary

Clinical trial endpoints for primary brain tumors will be the topic of the next public workshop in FDA's series of oncology endpoint meetings, to be held Jan. 20. "Issues identified in the workshop will be further discussed before the Oncologic Drugs Advisory Committee and thereafter will be detailed in FDA guidance documents," the agency said Nov. 22. The agency has previously hosted public meetings on lung, colorectal and prostate cancers (1"The Pink Sheet" June 28, 2004, p. 40). The workshop will be held at the Marriott in North Bethesda, Md., beginning at 8 a.m....

You may also be interested in...



Prostate Cancer Trial Composite PSA/Bone Scan Endpoint Suggested By FDA

FDA could consider an endpoint for prostate cancer trials that combines PSA kinetics and bone scan results, FDA Office of Cellular, Tissue & Gene Therapies Oncology Group Leader Steven Hirschfeld, MD/PhD, suggested

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel